These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32382808)

  • 1. Phase I pharmacological study of continuous chronomodulated capecitabine treatment.
    Roosendaal J; Jacobs BAW; Pluim D; Rosing H; de Vries N; van Werkhoven E; Nuijen B; Beijnen JH; Huitema ADR; Schellens JHM; Marchetti S
    Pharm Res; 2020 May; 37(5):89. PubMed ID: 32382808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.
    Jacobs BA; Deenen MJ; Pluim D; van Hasselt JG; Krähenbühl MD; van Geel RM; de Vries N; Rosing H; Meulendijks D; Burylo AM; Cats A; Beijnen JH; Huitema AD; Schellens JH
    Br J Clin Pharmacol; 2016 Sep; 82(3):706-16. PubMed ID: 27161955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy.
    Marok FZ; Wojtyniak JG; Selzer D; Dallmann R; Swen JJ; Guchelaar HJ; Schwab M; Lehr T
    Clin Pharmacol Ther; 2024 Jun; 115(6):1282-1292. PubMed ID: 38264789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
    Milano G; Chamorey AL
    Chronobiol Int; 2002 Jan; 19(1):177-89. PubMed ID: 11962674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Circadian variations of dihydropyrimidine dehydrogenase (DPD) activity in oral mucosa of healthy volunteers].
    Barrat MA; Renée N; Mormont MC; Milano G; Levi F
    Pathol Biol (Paris); 2003 Jun; 51(4):191-3. PubMed ID: 12852985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
    Fakih MG; Rajput A; Yang GY; Pendyala L; Toth K; Smith JL; Lawrence DD; Rustum YM
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1462-70. PubMed ID: 16750332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
    Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
    J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
    Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
    J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian variation in intestinal dihydropyrimidine dehydrogenase (DPD) expression: a potential mechanism for benefits of 5FU chrono-chemotherapy.
    Abolmaali K; Balakrishnan A; Stearns AT; Rounds J; Rhoads DB; Ashley SW; Tavakkolizadeh A
    Surgery; 2009 Aug; 146(2):269-73. PubMed ID: 19628084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences].
    Barrat-Petit MA; Naulin-Ifi C; Mahler P; Milano G
    Pathol Biol (Paris); 2005 Jun; 53(5):261-4. PubMed ID: 15939134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
    Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
    Vallböhmer D; Yang DY; Kuramochi H; Shimizu D; Danenberg KD; Lindebjerg J; Nielsen JN; Jakobsen A; Danenberg PV
    Int J Oncol; 2007 Aug; 31(2):413-8. PubMed ID: 17611699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
    Gbeto CC; Quaranta S; Mari R; Fanciullino R; Roche C; Nahon S; Solas C; Ouafik L; Lacarelle B; Allegre T; Ciccolini J
    Pharmacogenomics; 2019 Aug; 20(13):931-938. PubMed ID: 31486738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls.
    Raida M; Kliche KO; Schwabe W; Häusler P; Clement JH; Behnke D; Höffken K
    J Cancer Res Clin Oncol; 2002 Feb; 128(2):96-102. PubMed ID: 11862480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
    Kumar R; Lu SK; Minchom A; Sharp A; Davidson M; Gunapala R; Yap TA; Bhosle J; Popat S; O'Brien ME
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):375-83. PubMed ID: 26706729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
    Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
    Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parenteral nutrition decreases hepatic dihydropyrimidine dehydrogenase activity and modulates catabolism of 5-fluorouracil in rats.
    Taniguchi M; Yano M; Tsujinaka T; Ogawa A; Morita S; Kaneko K; Akiyama Y; Miki H; Monden M
    In Vivo; 2003; 17(3):219-23. PubMed ID: 12929570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
    Kobuchi S; Yazaki Y; Ito Y; Sakaeda T
    Eur J Pharm Sci; 2018 Jan; 112():152-158. PubMed ID: 29175408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
    Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
    Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
    Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.